Molecular mechanisms of metastasis in prostate cancer

Prostate Cancer: Principles and Practice

Volumn , Issue , 2005, Pages 383-400

  Clarke, Noel W ^a   Brown, Mick D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349124552     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (167)

1. Liotta L. Tumour invasion and metastases-role of the extracellular matrix. Rhodes Memorial Lecture. Cancer Res 1986;46:1-7.
2. Birchmeier W, Behrens J. Cadherin expression in carcinomas: the role in the formation of cell junctions and prevention of invasiveness. Biochem Biophys Acta 1994;1198:11-26.
3. Frixen U, Behrens J, Sachs M, et al. E-cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173-185.
4. Vleminckx K, Vakaet L Jr, Mareel M, et al. Genetic manipulation of Ecadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107-119.
5. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-1455.
6. Näthke I, Hinck L, Swedlow JR, et al. Defining interactions and distributions of cadherin and catenin complexes in polarized epithelial cells. J Cell Biol 1994;125:1341-1352.
7. Bussemakers M, van Moorselaar RJA, Giroldi LA, et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992;52:2916-2922.
8. Perl A, Wilgenbus P, Dahl U, et al. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190-193.
9. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-caherin is reduced or absent in high grade prostate cancer. Cancer Res 1992;52:5104-5109.
10. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-3933.
11. Cheng L, Nagabhushan M, Pretlow TP, et al. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Path 1996;148:1375-1380.
12. McWilliam L, Knox WF, Hills C, et al. E-cadherin expression fails to predict progression and survival in prostate cancer [Abstract]. J Urol 1996;155:516-526.
13. Bryden AAG, Freemont AJ, Clarke NW, et al. Paradoxical expression of E-cadherin in prostate bone metastases. Br J Urol 1999:84:1032-1034.
14. Mareel M, Behrens J, Birchmeier W, et al. Down regulation of Ecadherin expression in Madin Darby canine kidney (MDCK) cells inside tumors of nude mice. Int J Cancer 1991;47:922-928.
15. Ligtenberg M, Buijs F, Vos HL, et al. Suppression of cellular aggregation by high levels of episialin. Cancer Res 1992;52:2318-2324.
16. Shimoyama Y, Nagafuchi A, Fujita S, et al. Cadherin dysfunction in a human cancer cell line: possible involvement of loss of -catenin expression in reduced cell-cell adhesiveness. Cancer Res 1992;52:5770-5774.
17. Shimazu T, Schalken JA, Giroldi LA, et al. Prognostic value of cadherin associated molecules (alpha, beta, gamma catenins and p120cas) in bladder tumours. Cancer Res 1996:56:4154-4158.
18. Zheng Z, Pan J, Chu B, et al. Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum Pathol 1999;30:458-466.
19. Silye R, Karayiannakis AJ, Syrigos KN, et al. E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol 1998;186:350-355.
20. Morita N, Uemura H, Tsumatani K, et al. E-cadherin and alpha-, betaand gamma-catenin expression in prostate cancers: correlation with tumour invasion. Br J Cancer 1999;79:1879-1883.
21. Murant S, Handley J, Stower M, et al. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 1997;33:263-271.
22. Umbas R, Isaacs WB, Bringuier PP, et al. Relation between aberrant alpha catenin expression and loss of cadherin function in prostate cancer. Int J Cancer 1997;74:374-377.
23. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-426.
24. Voeller H, Truica CI, Gelmann EP. Beta-catenin mutations in prostate cancer. Cancer Res 1998;58:2520-2523.
25. Suzuki H, Aida S, Akimoto S, et al. State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer. Jap J Cancer Res 1994;85:847-852.
26. Honn K, Tang DG. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Rev 1992;11:353-375.
27. Cress A, Rabinovitz I, Zhu W, et al. The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev 1995;14:219-228.
28. Nagle R, Knox JD, Wolf C, et al. Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem 1994;19:232-237.
29. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer:innovations for the post-trial era. Nat Rev Cancer 2002;2:657-672.
30. Lokeshwar B, Selzer MG, Block NL, et al. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 1993;53:4493-4498.
31. Montague R, Hart CA, George NJ, et al. Differential inhibition of invasion and proliferation by bisphosphonates: anti metastatic potential of zoledronic acid in prostate cancer. Eur Urol 2004;46,389-402.
32. Hart CA, Scott LJ, Bagley S, et al. Role of proteolytic enzymes in prostate bone metastasis formation: in vitro and in vivo studies. Br J Canc 2002:86:1136-1142.
33. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002:2:563-572.
34. Lang S, Clarke NW, George NJ, et al. Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha2beta1 integrin. Clin Exp Metast 1997;15:218-227.
35. Lang S, Clarke NW, George NJR, et al. Interaction of prostate epithelial cells from benign and malignant tumor tissue with bonemarrow stroma. Prostate 1998;34:203-213.
36. Oxford G, Theodorescu D. Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett 2003;189:117-28.
37. Johnston SR. Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol 2001;2, 18-26.
38. Adjei A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001:93:1062-1074.
39. Hu L, Shi Y, Hsu JH, et al. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003;101:3126-3135.
40. Cohen LH, Pieterman E, van Leeuwen RE, et al. Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics. Biochem Pharmacol 2000;60:1061-1068.
41. Graham TE, Pfeiffer JR, Lee RJ, et al. MEK and ERK activation in rasdisabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling. J Immunol 1998;161:6733-6744.
42. Kelloff GJ, Lubet RA, Fay JR, et al. Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1997;6:267-282.
43. van Golen KL, Bao L, DiVito MM, et al. Reversion of RhoC GTPaseinduced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther 2002;1:575-583.
44. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001;97:1404-1412.
45. Giniger E. How do Rho family GTPases direct axon growth and guidance? A proposal relating signaling pathways to growth cone mechanics. Differentiation 2002;70:385-396.
46. Denoyelle C, Hong L, Vannier JP, et al. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003;88:1631-1633.
47. Khafagy R, Hart C, Stephens T, et al. In vitro effects of the prenyl transferase inhibitor AZD3409 on prostate cancer epithelial cells. Proc Asco 2004.
48. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the cMet receptor: a paradigm for mesenchymal-epithelial interaction. J Cell Biol 1994:127:1783-1787.
49. Cooper CS, Park M, Blair DG, et al Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33.
50. Knudsen BS, Edlund E. Prostate cancer and the cMet hepatocyte growth factor. Adv Cancer Res 2004:91:31-67.
51. Behrens J, Weidner K, Frixen UH, et al. The role of E cadherin and scatter factor in tumour invasion and cell motility. EXS 1991;59:109-126.
52. Rong S, Bodescot M, Blair DG, et al. Tumorigenicity of the met protooncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992;12:5152-5158.
53. Rong S, Segal S, Anver M, et al Invasiveness and metastasis of NIH-3T3 cells induced by met-hepatocyte growth factor / scatter factor autocrine stimulation. Proc Natl Acad Sci USA 1994;91:4731-4735.
54. Jeffers M, Rong S, Woude GE. Hepatocyte growth factor / scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996;74:505-513.
55. Jeffers M, Fiscella M, Webb CP et al. The mutationally activated met receptor mediates motility and metastasis. Proc Natl Acad Sci 1998;95:14417-14422.
56. Kurimoto S, Moriyama N, Horie S, et al. Co-expression of hepatocyte growth factor and its receptor in human prostate cancer. Histochem J 1998;30.
57. Van Leenders G, van Balken B, Aalders T, et al. Intermediate cells in normal and malignant prostate epithelium express cMet: Implications for prostate cancer invasion. Prostate 2002;51:98-107.
58. Bonkhoff H, Stein U, Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994;24:114-118.
59. Bonkhoff H. Analytical molecular pathology of epithelial-stromal interactions in the normal and neoplastic prostate. Anal Quant Cytol Histol 1998;20:437-432.
60. Humphrey P, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-396.
61. Pisters L, Troncoso P, Zhau HE, et al. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-298.
62. Watanabe M, Fukutome K, Kato H, et al. Progression linked overexpression of cMet in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett 1999;141:173-178.
63. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of cMet receptor in prostate cancer metastasis to bone. Urology 2002;60:1113-1117.
64. Birchmeier W, Brinkmann V, Niemann C, et al. Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found Symp 1997;212:230-240.
65. Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces wnt independent translocation of beta catenin after met-beta catenin dissociation in hepatocytes. Cancer Res 2002;62:2064-2071.
66. Lang SH, Clarke NW, George NJR, et al. Scatter factor influences the formation of prostate epithelial colonies in bone marrow stroma in vitro. Clin Exp Metastasis 1999;17:333-340.
67. Kim SJ, Johnson M, Koterba K, et al. Reduced cMet expression by an adenovirus expressing a cMet ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumour cells in an orthotopic nude mouse. Clin Canc Res 2003:9:5161-5170.
68. Miao H, Nickel CH, Cantley LG, et al. EphA kinase activation regulates HGF-induced epithelial branching morphogenesis. J Cell Biol 2003:162:1281-1292.
69. Fujiuchi Y, Nagakawa O, Murukami K, et al. Effect of hepatocyte growth factor on invasion of prostate cancer cell lines. Oncol Reports 2003;10:1001-1006.
70. Sloane JP, Ormerod MG, Neville AM. Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res 1980;40:3079-3082.
71. Diel IJ, Kaufmann M, Goerner R, et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534-1539.
72. Lindemann F, Schlimok G, Dirschedl P, et al. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;340:685-689.
73. Pantel K, Riethmuller G. Micrometastasis detection and treatment with monoclonal antibodies. Curr Top Microbiol Immunol 1996;213:1-18.
74. Cristofanilli M, Budd GT, Ellis M, et al. Circulating tumour cells, disease progression and survival in metastatic breast cancer. N Engl J Med 2004:351:824-826.
75. Berger U, Bettelheim R, Mansi JL, et al. The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol 1988;90:1-6.
76. Mansi JL, Easton D, Berger U, et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years’ follow-up. Eur J Cancer 1991;27:1552-1555.
77. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996;88:1652-1658.
78. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 1998;16:557-566.
79. Pantel K, Schlimok G, Angstwurm M, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994;3:165-173.
80. Slovin S F, Scher HI. Detectable tumor cells in the blood and bone marrow: smoke or fire? Cancer 1998;83:394-398.
81. Bhatt RI. Identification and Characterisation of the Putative Prostatic Stem Cell. Manchester University MD Thesis, 2005.
82. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999;91:1113-1124.
83. Pikarsky E, Peretz T. Bone marrow metastases in breast cancer. N Engl J Med 2000;343:577-578.
84. Straub B, Muller M, Krause H, et al. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using “Light-Cycler”-based quantitative real-time polymerase chain reaction. Urology 2001;58:815-820.
85. Heung YM, Walsh K, Sriprasad S, et al. The detection of prostate cells by the reverse transcription-polymerase chain reaction in the circulation of patients undergoing transurethral resection of the prostate. BJU Int 2000;85:65-69.
86. Eschwege P, Dumas F, Blanchet P, et al. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995;346:1528-1530.
87. Price DK, Clontz DR, Woodard WL 3rd, et al. Detection and clearance of prostate cells subsequent to ultrasound-guided needle biopsy as determined by multiplex nested reverse transcription polymerase chain reaction assay. Urology 1998;52:261-266; discussion 266-267.
88. Hart C, Brown M, Bagley S, et al. Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br J Cancer 2005:1-10.
89. Scott LJ, Hart C, Clarke NW, et al. Interactions of human prostate epithelial cells with bone marrow endothelium: binding and invasion. Br J Cancer 2001:84:1417-1423.
90. McIntyre IG, Bhatt RI, Clarke NW. Isolation of epithelial cells from blood and bone marrow of prostate cancer patients. Pros Cancer Pros Dis 2002:5:S21.
91. Alonso-Varona A, Palomares T, Bilbao P, et al. Tumor-host interaction in non-random metastatic pattern distribution. Bull Cancer 1996;83:27-38.
92. Brightmore T, Greening WP, Hamlin I. An analysis of clinical and histopathological features in 101 cases of carcinoma of breast in women under 35 years of age. Br J Cancer 1970;24:644-669.
93. Doyle A, Martin WJ, Funa K, et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 1985;161:1135-1151.
94. Concha A, Esteban F, Cabrera T, et al. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991;2:47-54.
95. Ruiter D, Mattijssen V, Broeker E-B, et al. MHC antigens in human melanomas. Semin Cancer Biol 1991;2:35-45.
96. Blades R, Keating PJ, McWilliam LJ, et al. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995;46:681-686.
97. Weiss L. Deformation driven lethal damage to cancer cells. Its contribution to metastatic inefficiency. Cell Biophys 1991;18:73-79.
98. Luzzi K, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998;153:865-873.
99. Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 1970;45:773-782.
100. Glaves D, Huben RP, Weiss L. Haematogenous dissemination of cells from human renal adenocarcinomas. Br J Cancer 1988;57:32-35.
101. Collins AT, Habib FK, Maitland NJ, et al. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)- integrin expression. J Cell Sci 2001;114:3865-3872.
102. Hudson DL, O’Hare M, Watt FM, et al. Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest 2000;80:1243-1250.
103. Brown M, Samuel J, Gilmore P, et al. Characterisation and phenotype of the recently defined prostate SP population: the quest for the prostate cancer stem cell. Proc ASCO 2005.
104. Bhatt RI, Brown M, Hart C, et al. A novel method for the isolation and characterization of the putative prostatic stem cell. Cytometry 2003:54A:89-99.
105. Orr F, Sanchez-Sweatman OH, Kostenuik P, et al. Tumour-bone interactions in skeletal metastases. Clin Orthopaedics Related Res 1995;312:19-33.
106. Lehr J, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 1998;90:118-123.
107. Tang D, Chen YQ, Newman PJ, et al. Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J Biol Chem 1993;268:22883-22894.
108. Zetter B. Adhesion molecules in tumor metastasis. Semin Cancer Biol 1993;4:219-229.
109. Voura E, Sandig M, Siu CH. Cell-cell interactions during transendothelial migration of tumor cells. Microsc Res Tech 1998;43:265-275.
110. Sneath R, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 1998;51:191-200.
111. Rabinovitz I, Nagle RB, Cress AE. Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exper Metast 1995;13:481-491.
112. Harsten M, Grove AS Jr, Woog JJ. The role of the integrin family of adhesion molecules in the development of tumors metastatic to the orbit. Ophthalmol Plas Recostruct Surg 1997;13:227-238.
113. Trikha M, Raso E, Cai Y, et al. Role of alphaII(b)beta3 integrin in prostate cancer metastasis. Prostate 1998;35:185-192.
114. Curry FE. Modulation of venular microvessel permeability by calcium influx into endothelial cells. Faseb J 1992;6:2456-2466.
115. Lewalle J, Calaldo D, Baiou K, et al. Endothelial cell intra cellular Ca2+ concentration is increased upon breast tumor cell contract and mediates tumour cell trans-endothelial cel migration. Clin Exp Metast 1998;16(1):21-29.
116. Pili R, Corda S, Passaniti A, et al. Endothelial cell Ca2+ increases upon tumor cell contact and modulates cell-cell adhesion. J Clin Invest 1993;92:3017-3022.
117. Virtanen SS, Vaananen HK, Harkonen PL, et al. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002;62:2708-2714.
118. Ohigashi H, Shinkai K, Mukai M, et al. In vitro invasion of endothelial cell monolayer by rat ascites hepatoma cells. Jpn J Cancer Res 1989;80:818-821.
119. Kramer RH, Nicolson GL. Interactions of tumor cells with vascular endothelial cell monolayers: a model for metastatic invasion. Proc Natl Acad Sci USA 1979;76:5704-5708.
120. Sandig M, Negrou E, Rogers KA. Changes in the distribution of LFA-1, catenins, and F-actin during transendothelial migration of monocytes in culture. J Cell Sci 1997;110, 2807-2818.
121. To C, Tsao MS. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers [Review]. Oncol Reports 1998;5:1013-1024.
122. Gohji K, Fujimoto N, Hara I, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Intl J Cancer 1998;79:96-101.
123. Hashimoto K, Kihira Y, Matuo Y, et al. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 1998;160:1872-1876.
124. Rabbani S, Harakidas P, Davidson DJ, et al. Prevention of prostatecancer metastasis in vivo by a novel synthetic inhibitor of urokinasetype plasminogen activator (uPA). Intl J Cancer 1995;63:840-845.
125. Van Veldhuizen P, Sadasivan R, Cherian R, et al. Urokinase-type plasminogen activator expression in human prostate carcinomas. Am Jf Med Sci 1996;312:8-11.
126. Kirchheimer J, Pfluger H, Ritschl P, et al. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Inv Metast 1985;5:344-355.
127. Taichman RS, Cooper C, Keller ET, et al. Use of the stromal cellderived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837.
128. Schrader AJ, Lechner O, Templin M, et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 2002;86:1250-1256.
129. Burger M, Glodek A, Hartmann T, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 2003;22:8093-8101.
130. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56.
131. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002;62:7328-7334.
132. Robledo MM, Bartolome RA, Longo N, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001;276:45098-45105.
133. Aiuti A, Webb IJ, Bleul C, et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997;185:111-120.
134. Hamada T, Mohle R, Hesselgesser J, et al. Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med 1998;188:539-548.
135. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000;106:1331-1339.
136. Aiuti A, Tavian M, Cipponi A, et al. Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lymphohematopoietic progenitors. Eur J Immunol 1999;29:1823-1831.
137. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999;283:845-848.
138. Staller P, Sulitkova J, Lisztwan J, et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425:307-311.
139. Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cellderived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000;6:3530-3535.
140. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;89:462-473.
141. Tamamura H, Hori A, Kanzaki N, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett, 2003;550:79-83.
142. Tokuda Y, Satoh Y, Fujiyama C, et al. Prostate cancer cell growth is mediated by adipocyte-cancer cell interaction. Br J Urol Int 2003;91:716-720.
143. Hart C, Brown M, Bagley S, et al. Influence of Omega 3 and Omega 6 lipids on prostate cancer cell migration and proliferation in human bone marrow stroma. 2005 In Submission
144. Nelson J, Bagnato A, Battistini B, et al. The endothelin axis: emerging role in cancer. Nat Cancer Rev 2003;3:110-116.
145. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic metastases. Cancer 2003:97:3:779-784.
146. Nelson J, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-949.
147. Nelson J, Lee WH, Nguyen SH, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663-668.
148. Nelson J, Nguyen SH, Wu-Wong JR, et al. New bone formation in an osteoblastic tumour model is increased by ET-1 overexpression and decreased by ET-A receptor blockade. Urology 1999;53:2063-2069.
149. Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption Br J Cancer 2000;83:360-365.
150. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-28.
151. Bryden AAG, Islam SH, Shanks JH, et al. Expression of PTH rP in bone metastases from prostate cancer. Prostate Cancer Prostate Dis 2002;40:673-676.
152. Bryden AAG, Hoyland J, Freemont AJ, et al. Parathyroid hormone related peptide and receptor expression in primary prostate cancer and bone metastases. Br J Cancer 2002;86:322-325.
153. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone related protein in the PTH like domain:inactivation of PTHrP stimulated camp accumulation in mouse osteoclasts. J Urol 1996;156:526-531.
154. Iwamura M, Hellman J, Cockett AT, et al. Alteration of the hormonal bioactivity of parathyroid hormone related peptide (PTHrP) as a result of limited proteolysis by prostate specific antigen. Urology 1996;48:317-325.
155. Cohen P, Peehl DM, Graves H, et al. Biological effects of prostate specific antigen as an insulin like growth factor binding protein 3 protease. J Endocrinol 1994;142:407-415.
156. Charhon SA, Chapoy MC, Devlin EE, et al. Histomorphometric analysis of sclerotic bone metastasis from prostatic carcinoma from prostate cancer with special reference to osteomalacia. Cancer 1983;51:918-924.
157. Clarke NW, McLure J, George NJR. Morphometric evidence for bone destruction and replacement in metastatic prostate cancer. Br J Urol 1991;68:74-80.
158. Clarke NW, McClure J, George NJR. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 1993;24:286-290.
159. Cook GB, Watson FR. Events in the natural history of prostate cancer:rising salvage, mean age distribution and contingency co-efficient. J Urol 1968;99:87-96.
160. Galasko CSB. Mechanisms of bone destruction in the development of skeletal metastases. Nature 1976;263:507-510.
161. Urwin GH, Percival RC, Harvey WJ, et al. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985;57:721-72.
162. Clarke NW, McClure J, George NJR. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol 1992;69-74.
163. Jung K, Lein M, Stephan C, et al. Comparison of 10 different bone turnover markers in prostatic carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004;111:783-791.
164. Suda T, Takahasi N, Udagawa N, et al. Modulation of osteoclast differentiation and function modulation by new members of the tumour factor receptor by new members of the tumour necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357.
165. Tietelbaum SL. Bone resorption by osteoclasts. Science 2000;289;1504-1508.
166. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-4458.
167. Guise TA, Mundy GR. Cancer and Bone. Endocr Rev 1998;19:18-54.